INTRODUCTION
Tissue damage associated with the acute inflammatory response, such as occurs after deposition of immune complexes, has been linked to a requirement for the complement system as well as neutrophils (1) . Com- plement activation products, namely C5a, serve as cheReceived for publication 18 March 1983 and in revised form 25 May 1983. moattractants to bring about accumulation of neutrophils within tissues (2) . At the same time, there is evidence that chemotactic peptides such as C5a can stimulate neutrophils in a manner that results in the generation of a family of toxic oxygen products, including superoxide anion (O°), H202, and other products such as the hydroxyl radical (OH') (reviewed, 3). After deposition of immune complexes and subsequent complement activation within lung alveoli, significant protection from injury can be accomplished by treatment of animals with catalase, suggesting that leukocytic production of H202 is a key event (4) .
In another model of acute lung injury, intravascular activation of complement after infusion of the C3 activator isolated from cobra venom results in acute lung injury with focal damage of endothelial cells lining the interstitial capillaries. The pathogenesis of this injury seems to involve the following steps: appearance of C5a in plasma, leukocytic activation, neutropenia, leukoaggregation, sequestration of neutrophils within the lung interstitial capillaries, and, finally, endothelial cell damage that can be blocked by the infusion of catalase and superoxide dismutase (5) .
In the studies to be presented, we demonstrate that, in the model of systemic complement activation, acute lung injury can be greatly diminished if interventions are used that reduce the availability of iron ions. Conversely, infusion of ionic iron potentiates the tissue damage. In addition, dimethyl sulfoxide (DMSO),' a potent scavenger of hydroxyl radical, protects against the tissue injury. These data support an increasing body of evidence suggesting that iron-catalyzed conversion of leukocyte-produced H202 into the hydroxyl radical (OH') is a critical step in events leading to acute tissue injury.
METHODS
Animal model of lung injury. As recently described (5) , pathogen-free adult (250 g), male Long Evans rats were used for the studies to be described. Approximately 4.0 units (50 jig protein) of cobra venom factor (CVF) were injected intravenously along with 5 jg '25I-bovine serum albumin. Either radiolabeled rat '25I-IgG or '251-bovine serum albumin can be used as markers of increased vascular permeability (4, 5) in lung, although precise comparisons between the two as markers of permeability have not been carried out. Animals were anesthetized with ketamine hydrochloride (Parke Davis and Co., Morris Plains, NJ) and exsanguinated 30 min later via the vena cava inferior. The lung vasculature was then perfused through the right cardiac ventricle with 10 ml phosphate-buffered saline (pH 7.4) . The lungs were removed and the amount of radioactivity remaining within the tissue assessed with a gamma scintillation counter. Lung damage was defined by the increased lung vascular permeability, as determined by the ratio of radioactivity present within lung tissue and the amount of radioactivity present in 1.0 ml venous blood obtained when the animals were killed. In a control animal, the ratio (defined as the permeability value) usually fell between 0.15 and 0. 25 Details of this animal model have been recently published (5) . When animals were subjected to various therapeutic interventions, the agents were injected intravenously together with CVF or intraperitoneally 10 min before vascular infusion of CVF. Preparation and characterization of lactoferrin. Lactoferrin was prepared from human breast milk by the procedures of Blackberg and Hernell (6) . Briefly, the fat-rich fraction was removed by flotation centrifugation. The preparation was then treated with HCI to renmove casein and subjected to chromatographic separation in a heparin-Sepharose column. To obtain apolactoferrin (iron free), the lactoferrin preparation was extensively dialyzed against 0.1 M citric acid to remove bound iron. The iron-saturated form of lactoferrin was prepared by the addition of 0.025 jimol of Fe3+/mg protein according to the procedure of Masson and Hleremans (7) . Nonbound iron was removed by dialysis of the lactoferrin in phosphate-buffered saline. By the ferrozine colorimetric method, the apolactoferrin preparation contained 80 ng Fe3+/mg apolactoferrin, while the iron-saturated preparation contained 1,120 ng Fe3+/mg lactoferrin. When analyzed by in vivo clearance studies, the lactoferrin preparations were first radiolabeled with 1251 by the lactoperoxidase method (8 (10) . Planimetry was used to determine the amounts of native and converted C3, the latter representing C3b.
Blood neutrophil counts. These were determined in the usual fashion with blood samples from tail veins delivered into acetic acid, followed by cell counts as assessed in hemocytometers.
Morphometric studies of lung. Table I . In experiment A, the intravenous infusion (0.5 ml) of saline and '25I-bovine serum albumin resulted in a base-line value for lung permeability of 0.18±0.02. As expected, the infusion of 4 injury. Similarly, the infusion into two rats of 1.0 mg iron-saturated lactoferrin failed to produce lung injury in the absence of CVF (lung permeability value of 0.09±0.03).
In experiments B and C, preparations of lactoferrin derivatized by PEG were used at much lower doses (100 Ag). In the former experiment, derivatized apolactoferrin conferred 61% protection from lung injury, whereas no protection was found with the use of derivatized lactoferrin that was iron saturated. That the protective effects of apolactoferrin were specific was shown by this result as well as by the finding that infusion of a mixture of CVF and bovine serum albumin (which has a molecular weight similar to apolactoferrin) failed to produce protection from lung injury. The results in experiment C were confirmatory of those of experiment B: 68% protection from lung injury occurred with the derivatized preparation of apolactoferrin, whereas when the same preparation was iron saturated, only 26% protection from lung injury occurred. These data indicate that either relatively high doses of nonderivatized apolactoferrin or much lower doses of derivatized apolactoferrin will confer significant protection against acute lung injury after systemic complement activation, whereas ironsaturated preparations of either form of lactoferrin have little or no protective function.
C3 conversion in protected and nonprotected animals. To determine whether protection against lung injury afforded by treatment of rats with apolactoferrin could be attributed to a blocking of complement activation after infusion of CVF, sera from rats treated with a variety of different materials, as described in Table I , were analyzed for evidence of C3 conversion by means of crossed immunoelectrophoresis. An example of this technique is shown in Fig. 4 4 Crossed immunoelectrophoretic analysis of serum C3 at 5 and 30 min after infusion of CVF into rats. Converted C3 (C3b) appears in the anodal position of each profile.
shown in Table II , sera from animals treated with saline revealed <11% converted C3 at 5 and 30 min after vascular infusion of saline. (This low level of C3 conversion appears to represent an artifact, since sera taken from untreated rats consistently showed 5-10% converted C3, probably the result of conversion occurring during in vitro manipulation of blood and serum). In animals injected with CVF, 45.3% of C3 appeared in the converted form at 5 min, declining to 36.4% at 30 min. In animals also treated with apolactoferrin under conditions that afforded protection from acute lung injury (Table I) , virtually identical amounts of converted C3 were found at the same intervals of time. In animals receiving CVF together with iron-saturated lactoferrin, 49.1% of the C3 appeared in the converted form at 5 min, whereas 43.1% was found at the 30-min interval. These data indicate that the protective effects of apolactoferrin are not associated with a blocking of the activation and conversion of C3 after infusion of CVF.
In additional studies, fresh rat serum was treated in vitro with CVF in the presence or absence of apolactoferrin, or iron-saturated lactoferrin, or with preparations of lactoferrin alone. Residual CH50 values were then measured. As the data in Table III indicate, addition of CVF to rat serum abolished measurable CH50 levels. The coincidental addition of apolactoferrin did not interfere with this loss of activity. The addition of lactoferrin alone (the apo form or the iron-saturated form) had a slight inhibitory effect (16%) on CH50 levels in rat serum. The reason for this slight reduction in serum CH50 levels in the presence of apolactoferrin is unknown. In companion studies, normal rat serum C3 was examined by crossed immunoelectrophoresis Where used, 4 units CVF, 1 .0 mg lactoferrin, and iron-saturated lactoferrin were injected in a total volume of 0.5 ml. were added to serum and the mixture incubated as described above.
in the presence or absence of apolactoferrin (1.0 mg/ ml serum). There was 9.1% C3 in the converted form in the absence of apolactoferrin; in its presence, 9.6% of C3 appeared in the converted form. Thus, the addition to serum of relatively high concentrations of apolactoferrin did not result in complement activation. These data, together with the fact that vascular infusion into the rat of 1.0 mg of apolactoferrin did not result in acute lung injury (Table I , experiment A), suggest that the protective effects of apolactoferrin on complement-mediated acute lung injury are not the result of apolactoferrin interfering with activation of the complement system by CVF or due to its induction of a consumptive depletion of the complement system.
In vivo effects of lactoferrin on leukocyte levels.
Because of some reports indicating that infusion of leukocytic lactoferrin can cause a neutropenia (11), it was important to determine whether this could be related to the protective effects of lactoferrin on complement-mediated acute lung injury, since neutrophils are known to play a key role in this reaction (5) . As shown in Fig. 5 , blood neutrophil counts were obtained after intravenous infusion of sterile saline, apolactoferrin, or iron-saturated lactoferrin (2.0 mg). For each of the three reagents used, two animals were used per group. In each of the three groups, the absolute neutrophil count fell to '50% of the starting value. In animals treated with saline or with apolactoferrin, the neutrophil counts returned to the pretreatment values within the first 5-10 min, whereas the animals treated with iron-saturated lactoferrin showed a persistent increase (doubling) in neutrophil counts after the first 5 min. of lactoferrin on lung injury after systemic complement activation.
Protection from CVF-induced lung injury by deferoxamine mesylate. In view of the data showing protective effects of apolactoferrin on CVF-induced acute lung injury but not with iron-saturated lactoferrin (Table I) , additional studies were carried out with the synthetic ferric ion chelator deferoxamine mesylate. This material was injected intravenously together with CVF. As demonstrated in Fig. 6 , there was a direct relationship between the amount of deferoxamine infused and the protection from acute lung injury. The dose of deferoxamine causing 50% of protection against lung injury under the conditions used was 1.0 mg/rat. That the protective effects of deferoxamine were not associated with a blocking of complement activation was shown by the fact that residual serum CH50 values in the sera of all animals treated with CVF and deferoxamine were <4 units/ml 30 min after infusion of CVF, similar to the values obtained in animals receiving CVF in the absence of deferoxamine (data not shown). In addition, serum from one animal given 2.0 mg deferoxamine with CVF showed that, by 30 min, 59% of the C3 was in the converted form as compared with 58% conversion of C3 in serum of a rat not given deferoxamine but otherwise treated similarly. These data indicate that the protective effects of deferoxamine are not related to interference with complement activation.
In studies to be reported elsewhere, the addition of deferoxamine (in concentrations as high as 1.0 mM) to suspensions of rat neutropils failed to impair the chemotactic responses of these cells to complementactivated rat serum (G. 0. Till, H. Tvedten, and P. A. Ward; paper to be submitted). These findings suggest that the in vivo protective effects of deferoxamine cannot be explained by a blocking of neutrophil activation.
Protective effects of DMSO on CVF-induced lung injury. In view of the known potent effects of DMSO as a hydroxyl radical scavenger (12), a series of rats was injected intraperitoneally with 1.0 ml DMSO 10 min before intravenous injection of CVF. As shown in experiment A (Table IV) , treatment of rats with DMSO (in the absence of CVF) had no lung-damaging properties; the mean lung permeability value for this group was 0.18±0.03, as compared with animals treated with saline alone, with a mean lung permeability value of 0.21±0.02. When animals were treated with CVF in the presence of DMSO, there was a substantial fall in the amount of lung injury (66% protection, Table IV) as compared with animals treated only with CVF.
In another series of studies (Table IV , experiment B), the protective effects of DMSO on CVF-induced lung injury were again demonstrated. Animals infused only with saline exhibited the expected base-line values of lung permeability (0.23±0.01), whereas infusion of CVF caused a fivefold increase in lung permeability (1.17±0.21), whereas the pretreatment of rats with DMSO resulted in a considerable attenuation (73.4%) of the lung injury, with a mean lung permeability value of 0.48±0.02. Sera from these two animals protected with DMSO were analyzed for C3 conversion 5 Morphological analysis of protected animals. Animals treated with CVF and killed 30 min later showed the expected morphological changes in lung. These findings were characterized by leukoaggregates within interstitial capillaries of lung and intraalveolar hemorrhage and fibrin deposits. At this magnification, there was also evidence of disruption of endothelial cells indicative of damage and/or destruction (Fig. 7  A, arrows) . In animals injected with CVF and also treated with 1.0 ml DMSO, aggregates of neutrophils were present within the interstitial capillaries, but there was no evidence of vascular damage. Endothelial with leukoaggregates ( Fig. 7 D) , in contrast to the findcells were intact and hemorrhage and fibrin were ab-ings in Fig. 7 A. sent (Fig. 7 B) . In another group of animals treated Under higher resolution, the areas in Fig. 7 A reveal with CVF as well as 2.0 mg apolactoferrin (conditions complete disruption of the endothelial cell lining with leading to protection from lung injury, Table I ), leu-evidence of amorphous proteinaceous debris adjacent koaggregates were also apparent within the interstitial to fibrin deposits, all of which abut against an exposed capillaries, but there was no evidence of hemorrhage basement membrane on one side and an intravascular or fibrin (Fig. 7 C) . At a higher magnification, endo-neutrophil on the other side (Fig. 8 A) . In contrast, a thelial cells were intact. The vascular basement mem-higher magnification of an area in Fig. 7 D (from an brane was not exposed so as to be in direct contact apolactoferrin-protected animal) reveals a neutrophil FIGURE 7 Transmission electron microscopic micrographs of rat lungs 30 min after intravenous infusion of CVF. In frame A, leukoaggregates are present within the interstitial capillaries of lung, along with intraalveolar hemorrhage and fibrin. There is also evidence of endothelial cell disruption (open arrows). In frame B, the animal also was treated with 2.0 ml DMSO. Leukoaggregates are present in the interstitial capillaries but endothelial cells are intact and no evidence of intraalveolar hemorrhage or fibrin is present. In frames C and D, sections of lungs from an animal injected with CVF and apolactoferrin (2.0 mg) reveal changes similar to those described in frame B. In frame D, the endothelial cells show no evidence of damage (closed arrows). Magnification of frames A, B, C is X4,100, while frame D is X10,500.
within the vascular compartment in direct contact with an intact endothelial cell lining (Fig. 8 B) . Fibrin deposits and proteinaceous debris are absent.
Morphometric studies of lung tissues. As described in an earlier section, morphometric analysis of lungs was undertaken to assess quantitative differences between animals developing the full extent of acute lung injury after intravenous injection with CVF and those animals that had been protected by pretreatment with apolactoferrin (described above). Using plastic imbedded tissue sections, we examined the lung interstitial capillary and the alveolar compartments. The data are summarized in Table V , where either linear distances (microns) reflecting surface areas or particle (cell) counts are recorded.
As is evident from the data, the interstitial capillary vessels in the saline-injected rats showed little evidence of bleb formation (0.73±0.81 Am/174±38.4 Am of total surface measured, or 0.41% of total surface area), whereas the CVF-treated animals showed a 30-fold increase in the amount of bleb formation (21.8±0.46 ,um), which represented 17.9% of the entire capillary surface area (121±12.2 ,m) examined. In contrast, animals protected with apolactoferrin showed a greatly attenuated amount of vascular surface area involved with bleb formation (2.1±0.99 um/122.7±16 ,um, or 1.72% of the total surface area being involved with bleb formation). There was a fivefold increase in numbers of neutrophils present within interstitial capillaries of CVF-treated rats as compared with rats treated with saline. For reasons that are not apparent, the animals treated with CVF and protective doses of apolactoferrin have nearly double the number of neutrophils within interstitial capillaries of the lung (Table  V) . As would be expected, for a given surface area of alveolar wall, there were few erythrocytes in tissues of rats injected intravenously with saline (0.007 erythrocytes/Mm alveolar wall) or with CVF and apolactoferrin (0.003 erythrocytes/,um alveolar wall), whereas in the CVF-treated animals there were 0.058 erythrocytes/,um alveolar wall (Table V) . Both the data dealing with bleb formation as well as those dealing with numbers of erythrocytes parallel the findings in which lung permeability changes were measured (Table I).
Potentiating effects of iron ion on CVF-induced lung injury. Since iron ion has a potentiating effect on the generation of hydroxyl radicals (13), rats were treated either with Fe3" (FeCi3) or with Fe2" (Fe[NH4]2[SO42) preparations together with CVF. As shown in Fig. 9 , Fe3+ in a dose-dependent manner had a potentiating effect on the CVF-induced acute lung injury. With 0.6 nmol, there was a 15% enhancement of lung injury, whereas 6 .0 nmol produced a 67% increase in the amount of lung injury. With higher concentrations (30 and 60 nmol), there was a return towards the values for lung injury (0.65±0.04) found in animals infused with CVF in the absence of iron salts. When a companion series of animals was studied, it was found that Fe2' also caused enhancement of lung injury, but the enhancing effects were quantitatively less than those found with Fe3+ (Fig. 9) . The intravenous infusion into two groups of two rats each of either 6 nmol FeCl3 or 60 nmol Fe(NH4)2(SO4)2 in the absence of CVF resulted in lung permeability values of 0.12±0.02 and 0.12±0.03, respectively, indicating that the iron salts in these concentrations are not capable of damaging the lung. It is possible that the relatively limited ability of Fe21 to potentiate lung injury was due to partial oxidation of Fe21 to Fe3".
DISCUSSION
In earlier studies, we demonstrated that infusion into rats of the C3 activator (isolated from cobra venom) results in acute lung vascular injury and that this injury depends on the availability of neutrophils and production of superoxide anion (°2) and H202 (5). We obtained direct morphological evidence of pulmonary vascular (capillary) endothelial cell injury, which was FIGURE 9 Potentiation of acute lung injury by iron salts after infusion of CVF. Fe3" causes substantial enhancement of lung injury when 6.0 nmol are infused intravenously. The effect is dose dependent; at higher concentrations the enhancing effect is lost. Fe2+ also has potentiating effects that were substantially less than those of Fe3+. Significance (P value) of each point is relative to the base line, which was determined by reference positive control values obtained in eight animals injected with CVF in the absence of iron salts.
always in proximity to leukoaggregates within capillaries. The mechanism responsible for the injury of endothelial cells was related to the generation of O2 and H202, but it was difficult to determine further the nature of the toxic oxygen products from activated neutrophils. Through manipulations that increase or decrease available ionic iron and by the use of a potent scavenger of OH', namely DMSO, evidence has now accumulated that strongly implies a role for OH' in the pathogenesis of the tissue damage.
It has been known for some time that iron has the ability, through its role as a redox agent, to alter the nature of oxygen metabolites derived from leukocytes or from other sources (3, 13 infusion of CVF into a rat was 1.76 ,ug/ml (determined by the ferrozine colorimetric method), of which free iron (measured in ultrafiltrates by the graphite furnace method) was 165 ng/ml, indicating that 9% of the total iron was in the free form. 30 min after infusion of CVF, the total iron was 2.09 Ag/ml, of which free iron was 347 ng/ml, indicating a near doubling (to 17%) in the amount of free iron in the serum. Although these data are preliminary, they suggest that free iron levels may increase in the course of CVF infusion, which could facilitate production of OH' radical by the mechanisms described above. Another reaction sequence related to OH' generation and a microbicidal outcome has recently been suggested by Klebanoff (22) , who described a bactericidal system dependent on the generation of OH' and the presence of iodide and Fe2 . Scavengers of OH' interfered with the killing mechanism, which occurred at acidic pH. It was presumed that an iodide derivative of OH' was the toxic agent, although this has not been proven. Whether a similar mechanism may be involved in acute lung injury after systemic activation of the complement system is not presently known.
Toxicity of ionic iron in rats may also be related to an interplay with H202 or other oxygen metabolites. Dougherty et al. (23) have recently demonstrated that the toxic effects following injection of Fe2+ or Fe3+ into rats are directly proportional to ethane production (which is taken as a reflection of lipid peroxidation). The toxicity can be greatly potentiated by prior exposure of the animals to diets deficient in either selenium or vitamin E. These observations have been explained by the natural antioxidant activity of vitamin E and the requirement for selenium in the activity of glutathione peroxidase.
Finally, there is increasing evidence that generation of toxic oxygen products by leukocytes may be a crucial factor in complications arising during infectious diseases. Clark and Hunt (24) have recently shown that the massive destruction of erythrocytes occurring in mice infected with Plasmodia vinckei can be blocked by the prior infusion of deferoxamine. They interpret the data to suggest that parasite death and erythrocyte destruction may be mediated by generation of reactive oxygen species, such as OH', and that this may be the reason for the destruction of nonparasitized erythrocytes and the endothelial cell damage that is known to occur in malaria. Indeed, the fact that substantial activation of the complement system is occurring in both plasmodial as well as babesial infections (25, 26) would be consistent with the idea that complement activation results in leukocytic activation, generation of H202, and its conversion in the presence of ionic iron to OH', and tissue injury.
It should also be noted that lactoferrin has effects on several mediator systems. Oseas et al. (27) have recently suggested that leukocytic lactoferrin may play an important role in facilitating leukocytic adhesion to other leukocytes and to endothelial cells. This may be the reason for the ability of lactoferrin to cause a brief neutropenia when injected intravenously (11) . Lactoferrin has also been described to block complement activation via the classical pathway (28), although this appears not to be relevant to the studies described above. Finally, lactoferrin appears to have the ability to facilitate or to diminish bactericidal activity of leukocytes (as referred to above), perhaps being directly related to its effects locally on the availability of ionic iron and thus the generation of OH'.
The studies in this report provide additional evidence for the role of toxic oxygen radicals by leukocytes activated in vivo by complement products and suggest that the conversion of H202 to OH' in the presence of ionic iron may be a key step in the ensuing tissue damage. These observations may have broad significance for tissue injury in a variety of conditions where complement activation products and neutrophils play a requisite role.
